Novo Nordisk AS (NVO)
105.06
+2.43
(+2.37%)
USD |
NYSE |
Nov 22, 16:00
105.08
+0.02
(+0.02%)
Pre-Market: 20:00
Novo Nordisk Cash from Investing (Quarterly): -3.131B for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Historical Cash from Investing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -3.131B |
| June 30, 2024 | -2.998B |
| March 31, 2024 | 576.22M |
| December 31, 2023 | -2.112B |
| September 30, 2023 | -1.932B |
| June 30, 2023 | -1.370B |
| March 31, 2023 | -958.59M |
| December 31, 2022 | -2.034B |
| September 30, 2022 | -624.14M |
| June 30, 2022 | -586.61M |
| March 31, 2022 | -287.67M |
| December 31, 2021 | -3.285B |
| September 30, 2021 | -712.41M |
| June 30, 2021 | -467.55M |
| March 31, 2021 | -564.29M |
| December 31, 2020 | -1.940B |
| September 30, 2020 | -985.15M |
| June 30, 2020 | -201.98M |
| March 31, 2020 | -310.91M |
| December 31, 2019 | -489.26M |
| September 30, 2019 | -354.97M |
| June 30, 2019 | -420.93M |
| March 31, 2019 | -460.53M |
| December 31, 2018 | -668.98M |
| September 30, 2018 | -424.66M |
| Date | Value |
|---|---|
| June 30, 2018 | -395.27M |
| March 31, 2018 | -424.64M |
| December 31, 2017 | -461.63M |
| September 30, 2017 | -329.06M |
| June 30, 2017 | -110.38M |
| March 31, 2017 | -99.13M |
| December 31, 2016 | -400.61M |
| September 30, 2016 | -398.83M |
| June 30, 2016 | 27.64M |
| March 31, 2016 | -237.45M |
| December 31, 2015 | -698.28M |
| September 30, 2015 | -490.12M |
| June 30, 2015 | 2.192M |
| March 31, 2015 | 278.99M |
| December 31, 2014 | -281.54M |
| September 30, 2014 | -187.12M |
| June 30, 2014 | 24.15M |
| March 31, 2014 | 76.37M |
| December 31, 2013 | -93.55M |
| September 30, 2013 | -355.89M |
| June 30, 2013 | 25.23M |
| March 31, 2013 | -69.55M |
| December 31, 2012 | -291.05M |
| September 30, 2012 | -294.91M |
| June 30, 2012 | 120.97M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
-3.285B
Minimum
Dec 2021
576.22M
Maximum
Mar 2024
-1.221B
Average
-835.50M
Median
Cash from Investing (Quarterly) Benchmarks
| Ascendis Pharma AS | -- |
| Amgen Inc | -210.00M |
| AstraZeneca PLC | -1.514B |
| Viking Therapeutics Inc | 25.90M |
| Evaxion Biotech AS | -- |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 6.658B |
| Cash from Financing (Quarterly) | -2.741B |
| Free Cash Flow | 9.828B |
| Free Cash Flow Per Share (Quarterly) | 1.064 |
| Free Cash Flow to Equity (Quarterly) | 4.406B |
| Free Cash Flow to Firm (Quarterly) | 4.748B |
| Free Cash Flow Yield | 2.09% |